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Abstract:	  
 
A fourteen-year-old male was treated for non-metastasized femoral Ewing’s Sarcoma with inductive and 
consolidation chemotherapy together with surgical resection of the diaphysis with interposition of an 
allograft. During follow-up, a remarkable increase in osteoblastic activity in the distal osteotomy plane was 
seen on 99mTc-HDP scintigraphy 29 months after surgery that was highly suspicious of recurrence. Revision 
of radiographs showed delayed consolidation, induced by failure of hardware as the cause of increased 
tracer uptake. This was confirmed 6 months later by scintigraphy. Conclusion: Bone scintigrams should be 
interpreted with available conventional X-rays to avoid false-positive results. 
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Legends:	  
Figure 1: Anterior planar bone scintigrams made 4h after injection of ~500Mbq 99mTc-disodium 
hydroxymethylene diphosphonate (HDP) during follow-up of a patient with Ewing’s sarcoma (ES). Images 
are resized to the same patient height.  
A 14-year old boy initially presented with leg pain without trauma. Pre-treatment bone scintigraphy showed 
increased tracer concentration in the right femoral diaphysis on both early (not displayed) and late (A) 
series. In accordance with magnetic resonance imaging (MRI), which is suggested to be superior for local 
staging of ES due to its superior accuracy in assessing intramedullary and soft tissue extension1, 2, this was 
most likely due to osteomyelitis. However, malignancy could not be excluded (differential diagnosis: ES 
and hematological malignancies). Histopathological examination proved ES. There was no evidence of 
metastases on chest CT3 and whole-body 18F-FDG PET/CT4-8. 
He was treated according to the EURO-E.W.I.N.G. protocol with a four-drug induction regimen, consisting 
of 6 cycles of vincristine, ifosfamide, doxorubicin and etoposide (VIDE) and a three-drug post-operative 
regimen consisting of 8 cycles of vincristine, actinomycin D and ifosfamide (VAI).9, 10 In total 17cm of the 
femoral diaphysis was resected followed by reconstruction by an allograft femur shaft, a retrogradely 
placed intramedullary locked nail and a fixed angle femoral plate with screws. The resected diaphysis was 
without any sign of viable tumor cells. Since most relapses occur in the first three years (but can arise up to 
19 years after surgical resection11) careful follow-up for both recurrence and long-term sequelae of therapy, 
at least 4-6 times per year in the first three years, twice a year up to 5 years after treatment and at least once 
a year thereafter is warranted.10 This should include imaging for local recurrence by conventional X-ray, 
99mTc diphosphonate bone scintigraphy and chest X-ray for pulmonary metastases. 
Follow-up (B-D) by 99mTc-HDP bone scintigraphy showed decreasing osteoblastic activity at the proximal 
osteotomy plane corresponding to progressive fracture healing, but a stable and increased bone turnover up 
to 2 years postoperative (p.o.) in the distal anastomosis. Two and a half years p.o. (E), there was a sudden 
increase in osteoblastic activity which was highly suspicious of recurrent ES. 
 
Figure 2: Anteroposterior conventional X-rays during postoperative surveillance of this patient scaled to 
the same femoral length. Progressive consolidation of the proximal osteotomy plane can be seen while 
healing of the distal anastomosis is delayed up to two years post-surgery (A-E) corresponding to the 99mTc-
HDP scintigrams. First, the distal anti-rotation screw breaks (C) followed by failure of the femoral plate (F, 
figure 3), possibly due to extra stress on this piece of hardware. Fracture of hardware occurs in 
approximately 13% of the cases.12 As a consequence, progressive consolidation and callus formation of the 
distal junction (F) is initiated, visible 29 months post-operatively. Union rate in these kind of allograft 
reconstructions is around 25%.12 Interpretation of the bonescans without knowledge of time-dependent 
anatomical changes therefore may lead to the incorrect conclusion of recurrent ES instead of delayed union. 
 
Figure 3: Lateral (left) and anteroposterior (right) detail of the distal osteotomy plane 29 months 
postoperative. The fracture of the femoral plate (arrows) causing the delayed consolidation can be seen. 
  
 Figure 4: Bone scintigram 4 hours after injection of ~500MBq of 99mTc-HDP (left) and plain 
anteroposterior conventional X-ray (right) 6 months later (35 months postoperative). The radiograph shows 
progressive healing of the distal osteotomy plane. Correspondingly the bone scan shows decreasing 
osteoblastic activity in comparison to the previous scan, confirming the diagnosis. 
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